Evidence map›Paper›PMID 29342180›Full record

ArticlePloS one2018

Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa.

Charles B Holmes, Constantin T Yiannoutsos, Batya Elul, Elizabeth Bukusi, John Ssali, Andrew Kambugu, Beverly S Musick, Craig Cohen, Carolyn Williams, Lameck Diero and 2 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 4 countries.

Charles B HolmesCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.ORCID 0000-0002-7924-6761
Constantin T YiannoutsosIndiana University R.M. Fairbanks School of Public Health, Indianapolis, Indiana, United States of America.
Batya ElulMailman School of Public Health, Columbia University, ICAP at Columbia University, New York, New York, United States of America.
Elizabeth BukusiCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
John SsaliMasaka Regional Hospital, Masaka, Uganda.
Andrew KambuguInfectious Diseases Institute, Kampala, Uganda.
Beverly S MusickIndiana University School of Medicine, Indianapolis, Indiana, United States of America.
Craig CohenUniversity of California San Francisco, San Francisco, California, United States of America.
Carolyn WilliamsNational Institute of Allergies and Infectious Diseases, Bethesda, Maryland, United States of America.
Lameck DieroAcademic Model Providing Access to Health Care (AMPATH), Eldoret, Kenya.
Nancy PadianUniversity of California, Berkeley, California, United States of America.
Kara K Wools-KaloustianIndiana University School of Medicine, Indianapolis, Indiana, United States of America.
Indiana University School of MedicineAMPATH · KECentre for Infectious Disease Research in Zambia · ZMICAP Global HealthIndiana University – Purdue University Indianapolis · USInfectious Diseases Institute · UGKenya Medical Research Institute · KEMasaka Hospital · UGNational Institute of Allergy and Infectious Diseases · USUniversity of California, Berkeley · USUniversity of California, San Francisco · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
NIAID NIH HHS P30 AI027763NIAID NIH HHS U01 AI069911
6 · The paper itself

Abstract

backgroundThe World Health Organization now recommends initiating all pregnant women on life-long antiretroviral therapy (ART), yet there is limited information about the characteristics and program outcomes of pregnant women already on ART in Africa. Our hypothesis was that pregnant women comprised an increasing proportion of those starting ART, and that sub-groups of these women were at higher risk for program attrition. METHODS AND

findingsWe used the International Epidemiology Databases to Evaluate AIDS- East Africa (IeDEA-EA) to conduct a retrospective cohort study including HIV care and treatment programs in Kenya, Uganda, and Tanzania. The cohort consecutively included HIV-infected individuals 13 years or older starting ART 2004-2014. We examined trends over time in the proportion pregnant, their characteristics and program attrition rates compared to others initiating and already receiving ART. 156,474 HIV-infected individuals (67.0% women) started ART. The proportion of individuals starting ART who were pregnant women rose from 5.3% in 2004 to 12.2% in 2014. Mean CD4 cell counts at ART initiation, weighted for annual program size, increased from 2004 to 2014, led by non-pregnant women (annual increase 20 cells/mm3) and men (17 cells/mm3 annually), with lower rates of change in pregnant women (10 cells/mm3 per year) (p<0.0001). There was no significant difference in the cumulative incidence of program attrition at 6 months among pregnant women starting ART and non-pregnant women. However, healthy pregnant women starting ART (WHO stage 1/2) had a higher rate of attrition rate (9.6%), compared with healthy non-pregnant women (6.5%); in contrast among women with WHO stage 3/4 disease, pregnant women had lower attrition (8.4%) than non-pregnant women (14.4%). Among women who initiated ART when healthy and remained in care for six months, subsequent six-month attrition was slightly higher among pregnant women at ART start (3.5%) compared to those who were not pregnant (2.4%), (absolute difference 1.1%, 95% CI 0.7%-1.5%).

conclusionsPregnant women comprise an increasing proportion of those initiating ART in Africa, and pregnant women starting ART while healthy are at higher risk for program attrition than non-pregnant women. As ART programs further expand access to healthier pregnant women, further studies are needed to better understand the drivers of loss among this high risk group of women to optimize retention.

Indexed as

Patient CompliancePatient DropoutsAdultAfrica, EasternAnti-HIV AgentsFemaleHIV InfectionsHumansPregnancyPregnancy Complications, InfectiousPrevalenceYoung AdultAnti-HIV Agents

Identifiers

PMID29342180
PMCPMC5771608
OpenAlexW2786218762

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.